




CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 37 Number 3 May 2010



See Page A-2 for figure legend

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

Beyond technology


there's possibility




Over 40 years ago Professor Lars Leksell invented Gamma Knife® surgery, a revolutionary, non-invasive way to perform brain surgery that created new treatment possibilities for patients with inoperable brain cancer. Today, Leksell Gamma Knife® Perfexion™ is the cornerstone of a complete line of stereotactic treatment and radiosurgery solutions that is still creating new possibilities for the most challenging cases of the brain, head & neck, and body. Find out more at elekta.com/proof.



Elekta Axesse™



Leksell Gamma Knife® Perfexion™



Extend™ program

Human care makes the future possible



EDITORIALS

- 301** Death and Injury Due to All-Terrain Vehicles - A Disturbing Trend
Patrick McDonald
- 302** Familial Alzheimer Disease in Canada
Nicolas Dupré, Robert Laforce Jr.
- 304** What Means Familial?
F. Clarke Fraser
- 305** Where are we Going with Drugs to Treat MS? Will Cost Continue to Increase?
Où allons-nous avec les traitements de la SEP? Les coûts vont-ils continuer à augmenter?
Joel Oger, Mona AlKhawajah
- 309** The Tolerability and Efficacy of Levetiracetam
Jose F. Tellez-Zenteno
- 310** Canadian Health Care Explained to U.S. Colleagues: the Good, the Bad and the Ugly
J. Max Findlay

HISTORIAL REVIEW

- 313** Substantia Nigra and Parkinson's Disease: A Brief History of Their Long and Intimate Relationship
Martin Parent, André Parent

REVIEW ARTICLES

- 320** Carotid Revascularization: An Update
Cian J. O'Kelly, Ken S. Butcher, B. Elaine Marchak, J. Max Findlay
- 336** Autopsy as Gold Standard in FDG-PET Studies in Dementia
Pascali Durand-Martel, Dominic Tremblay, Catherine Brodeur, Nancy Paquet

ORIGINAL ARTICLES

- 343** Examining Ontario Deaths Due to All-Terrain Vehicles, and Targets for Prevention
Sarah Lord, Charles H. Tator, Sandy Wells

- 350** Early Onset Epilepsy and Inherited Metabolic Disorders: Diagnosis and Management
Asuri N. Prasad, G.F. Hoffmann
- 359** A Novel PS1 Gene Mutation in a Large Aboriginal Kindred
Rachel Butler, B. Lynn Beattie, Umamon Puang Thong, Emily Dwosh, Colleen Guimond, Howard H. Feldman, Ging-Yuek Robin Hsiung, Ekaterina Rogaeva, Peter St. George-Hyslop, A. Dessa Sadovnick
- 365** Deregulated Expression of the *Per1* and *Per2* in Human Gliomas
He-chun Xia, Zhan-feng Niu, Hui Ma, Shuan-zhu Cao, Shao-cai Hao, Zhong-tao Liu, Fan Wang
- 371** Microembolic Signals in Patients with Systemic Lupus Erythematosus
Mahmoud Reza Azarpazhooh, Naghmeh Mokhber, Elias Orouji, Brian R. Chambers, Mohammad Reza Hatf, Zahra Rezaeiyazdi, Sima Sedighi, Mohsen Foroghipoor, Arash Velayati, Morteza Modares Gharavi
- 376** Levetiracetam in Clinical Practice: Efficacy and Tolerability in Epilepsy
Leonilda Bilo, Maria Fulvia de Leva, Roberta Meo
- 383** Increasing Use of Disease Modifying Drugs for MS in Canada
Dalia L. Rotstein, Muhammad Mamdani, Paul W. O'Connor
- 389** Familial Occurrence of Complex Regional Pain Syndrome
Peyman Shirani, Ali Jawaid, Paolo Moretti, Elham Lahijani, Alicia R. Salamone, Paul E. Schulz, Everton A. Edmondson

NEUROIMAGING HIGHLIGHTS

- 395** The "Reversal Sign" Following a Massive Left-Hemispheric Stroke
Philippe Huot, François Émond
- 397** Delayed Neurological Deterioration in ICH Due to Cerebral Infarction
B.K. Menon, J. Singh, M.D. Hill
- 400** Spinal Cord Transection in a Child After Non-Penetrating Trauma
Fred A. Zeiler, Patrick J. McDonald

BRIEF COMMUNICATIONS

- 402** Hypophysitis Secondary to a Ruptured Rathke Cleft Cyst
Nancy McLaughlin, François Lavigne, Shaun Kilty, France Berthelet, Michel W. Bojanowski
- 406** Hydroxyzine Hydrochloride in Familial Restless Legs Syndrome
Roberto Di Fabio, Carlo Casali, Rita Vadalà, Francesco Pierelli
- 408** Middle Cerebral Artery Embolectomy After Failed Mechanical Clot Removal
Brian Drake, Gary Redekop
- 412** Status Epilepticus Due to Hyperfusion Injury Post Cardiac Surgery
Nir Lipsman, Richard Farb, Osman O. Al-Radi, Leanne K. Casaubon
- 416** Primary Choroid Plexus Papilloma of the Cauda Equina. A Case Report
Ryan DeMarchi, Hisham Al Khalidi, Mahmood Fazl, Juan M. Bilbao
- 419** Charcot Ankle Arthropathy in CMT1A Exacerbated by Type 2 Diabetes Mellitus
Natalie E. Parks, Timothy J. Benstead

REFLECTIONS

- 422** Olive
Mark Bernstein

CORRESPONDENCE

- 423** Letters to the Editor
- 425** Books Received/Books Reviewed
- 428** Calendar of Events
- A-13** Board of Directors/Committee Chairs
- A-3** CNSF 2010 Congress Program
- IBC** CNSF Sponsors
- A-9** Information for Authors
- A-10** Information for Authors
- A-17** Advertisers Index
- A-17** Classified Ads
- A-22** Annual Congress Registration and Hotel Details

COVER LEGEND

From the article "Hypophysitis Secondary to a Ruptured Rathke Cleft Cyst" pages 402-405
 Top Photo: Intraoperative view. A) Through an endoscopic endonasal transphenoidal approach, the sella was reached.
 B) After incision of the dura, a whitish creamy fluid flowed from the cyst.
 Bottom Photo: Pathology examination. H&E stain (A & B). A) Lymphocytes, plasma cells and multinucleated giant cells indicated a chronic granulomatous reaction. A simple epithelium with ciliated cells covered the pituitary tissue.
 B) Necrosis with cholesterol clefts surrounded by inflamed pituitary tissue.

Canadian Neurological Science Federation
Congress/ congrès
 Fédération des sciences neurologiques du Canada

Québec, Québec
 June/juin 8-11, 2010

Photos Courtesy of: de le Ministère du Tourisme du Québec/Mondoux, Louise(1)- Bourdeau, Jacques(2) - Hurteau, Paul; Parent, Claude(3) - Hurteau, Paul; Parent, Claude(4) - Lambert, Pierre; Parent, Claude(5) and to right

2010 CONGRESS-AT-A-GLANCE

**tuesday
 june 8**

- 07:45 - 17:00 Advances in the Neurobiology of Disease - **Peter Smith, Zelma Kiss**
- 07:50 - 17:30 Epilepsy Review Course for Neuroscience Residents - **Jose Martin del Campo**
- 08:00 - 17:00 Neurosurgery Resident Review Course: Neurovascular Disease
 - **J. Max Findlay, Shobhan Vachhrajani**
- 08:30 - 17:00 ALS - **David Cameron**
- 08:30 - 17:00 Child Neurology Day - **Cecil Hahn, Michelle Demos**
- 12:00 - 13:30 Co-developed Industry Symposium (Stroke)
- 18:00 - 20:00 Epilepsy Video Session - **Richard McLachlan**
- 18:00 - 20:00 SIGS (Movement Disorders - **David Grimes, Alex Rajput**, Headache - **Werner Becker**,
 Neuromuscular Diseases - **Kristine Chapman**)

**wednesday
 june 9**

- 06:30 - 08:00 Co-developed Symposium (Headache)
- 08:00 - 10:00 Grand Opening Plenary -Scientific & Technical Advances in the Clinical Neurosciences:
Jim Rutka (Penfield Lecture), Anthony Lang (Richardson Lecture), Josep Dalmau (Tibbles Lecture)
- 10:00 - 10:15 Break
- 10:15 - 11:45 Chairs' Select Plenary Presentations
- 12:00 - 13:30 Co-developed Symposium (Epilepsy)
- 12:00 - 13:30 Co-developed Symposium (Neuropathic Pain)
- 13:30 - 17:00 Headache - **Jonathan Gladstone**
- 13:30 - 17:00 Stroke - **Ariane Mackey**
- 13:30 - 17:00 Neurovascular Surgery - **R. Loch MacDonald**
- 13:30 - 17:00 Epilepsy - **S. Nizam Ahmed**
- 13:30 - 17:00 Neuro-oncology - **David Eisenstat**
- 13:30 - 17:00 Multiple Sclerosis - **Francois Emond**
- 17:00 - 19:30 Exhibitors Reception

**thursday
 june 10**

- 08:30 - 10:00 Plenary-CNS, CSCN, & CACN Neurology - **Cam Tesky (Gloor Lecture), John Stewart**
- 08:30 - 10:00 Plenary-CNSS Neurosurgery - **Stephan Mayer, Ziya Gokaslan**
- 10:00 -10:15 Break
- 10:15 - 12:30 Platforms (7 simultaneous)
- 12:30 - 14:00 Lunch/Exhibit Viewing/Digital Mini-platforms
- 14:00 - 16:30 Platforms (7 simultaneous)
- 16:30 - 18:30 Digital Poster and Exhibit Viewing

**friday
 june 11**

- 08:00 - 08:15 Journal Editor's Report
- 08:15 - 08:30 CBANHC Report
- 08:30 - 09:30 Distinguished guest lecture - **James Orbinski**
- 09:30 - 09:45 Currently Active Canadian Clinical Trials
- 09:45 - 10:15 Break/Exhibit viewing
- 10:15 - 12:00 Grand Rounds
- 12:00 - 13:30 Lunch / Exhibit viewing / Digital Mini-platforms
- 13:30 - 17:00 Neuro-ophthalmology - **William Fletcher**
- 13:30 - 17:00 Interventional Neuroradiology - **Alain Weill**
- 13:30 - 17:00 What's New in Neurosurgery - **Pascale Lavoie**
- 13:30 - 17:00 Neurocritical Care - **Draga Jichici, Jeanne Teitelbaum**
- 13:30 - 17:00 Neuromuscular Diseases - **Annie Dionne, Chris White**
- 13:30 - 17:00 Spine - **Eric Massicotte**
- 13:30 - 17:00 What's New in Neurology - **Nicolas Dupre**
- 13:30 - 17:00 EEG - **Seyed Mirsattari**

**friday
 june 11**



Editor-in-Chief/Rédacteur en chef

G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB
Michael Shevell MONTREAL, QC
Timothy J. Benstead HALIFAX, NS
Mike Poulter LONDON, ON
Serge Gauthier VERDUN, QC
Robert Hammond LONDON, ON

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Conseil d'éditorial

Jorge Burneo LONDON, ON
Richard Desbiens QUEBEC CITY, QC
David Fortin SHERBROOKE, QC
Mark Hamilton CALGARY, AB
Hans-Peter Hartung DUSSELDORF, GERMANY
Michael Hill CALGARY, AB
Alan C. Jackson WINNIPEG, MB
Daniel Keene OTTAWA, ON
Terence Myles CALGARY, AB
James Perry TORONTO, ON
Oksana Suchowersky CALGARY, AB
Brian Toyota VANCOUVER, BC
Brian Weinschenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

Richard Farb TORONTO, ON
David Pelz LONDON, ON

**Neuropathological Conference/Conférence
sur la neuropathologie**

Robert Hammond LONDON, ON

Book Review/Critiques de livres

Reflections/Reflets
Andrew Kirk SASKATOON, SK

**Critically Appraised Topic Summaries
(CATS)**

Jorge Burneo LONDON, ON
Mary Jenkins LONDON, ON

e-CPD (Web) Editor

Mandar Jog LONDON, ON

**Editorial Review Board/Conseil de
Revue d'éditorial**

Donald Brunet KINGSTON, ON
Lionel Carmant MONTREAL, QC
Colin Chalk MONTREAL, QC
K. Ming Chan EDMONTON, AB
Robert Chen TORONTO, ON
Mary Connolly VANCOUVER, BC
Joseph Dooley HALIFAX, NS
Daryl Fournay SASKATOON, SK
Hannah Glass SAN FRANCISCO, CA, USA
Alan Goodridge ST. JOHN'S, NL
Ian Grant HALIFAX, NS
Alan Guberman OTTAWA, ON
John Hurlbert CALGARY, AB
Manouchehr Javidan VANCOUVER, BC
Patrick McDonald WINNIPEG, MB
Martin McKeown VANCOUVER, BC
Joseph Megyesi LONDON, ON
Vivek Mehta EDMONTON, AB
Steven Miller VANCOUVER, BC
Neelan Pillay CALGARY, AB
Christopher Power EDMONTON, AB
Alex Rajput SASKATOON, SK
Jean Raymond MONTREAL, QC
Gary Redekop VANCOUVER, BC
Mark Sadler HALIFAX, NS
Harvey Sarnat CALGARY, AB
John Stewart VANCOUVER, BC
Jeanne Teitelbaum MONTREAL, QC
Eve Tsai OTTAWA, ON
Shannon Venance LONDON, ON
Matt Wheatley EDMONTON, AB
Jerome Yager EDMONTON, AB

Journal Staff - Calgary, AB

Dan Morin, *Chief Executive Officer*
Maggie McCallion, *Designer/*
Production Coordinator
Cindy Leschyshyn, *Editorial Coordinator*

**Advertising representative/Représentant de
publicité:**

Brett Windle
Corporate Development Coordinator
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE
Calgary, Alberta T2G 4B9

The official journal of: / La Revue officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:
Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est située en permanence à:

7015 Macleod Trail SW, Suite 709
Calgary, Alberta, Canada T2H 2K6

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals are: C\$120 (Canada), C\$140 (Foreign including USA). Subscription rates for Institutions are: C\$150 (Canada), C\$170 (Foreign including USA). See www.cjns.org for details. Single copies C\$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Web: www.cjns.org
COPYRIGHT© 2010 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Postage paid at Calgary, Alberta. This journal is indexed by *AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerptMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsychInfo, Reac, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCprem.*

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 \$C (non-membres au Canada); 140 \$C (Etats Unis et ailleurs); l'abonnement annuel pour les institutions est de 150 \$C (non-membres au Canada); 170 \$C (Etats Unis et ailleurs); Voir www.cjns.org pour détails. Copie simple: 30 \$C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Web: www.cjns.org. DROITS D'AUTEUR© 2010: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerptMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsychInfo, Reac, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCprem.*

ISSN 0317 - 1671

Pr**MAXALT RPD**[®]

(rizatriptan benzoate):

The Most Dispensed
Non-tablet Formulation
Migraine Drug
in Canada¹

Fast dissolving
RPD wafer can be taken
anytime, anywhere^{2,*}

ALSO AVAILABLE IN
TABLET FORMULATION.



MAXALT[®] (rizatriptan benzoate) is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT[®] is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of MAXALT[®] have not been established for cluster headache, which is present in an older, predominantly male population.

MAXALT[®] is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases should not receive MAXALT[®].

MAXALT[®] is also contraindicated in patients with uncontrolled or severe hypertension.

MAXALT[®] is contraindicated in co-administration with monoamine oxidase (MAO) inhibitors within 2 weeks after discontinuation of treatment, and within 24 hours of administration of 5-HT₁ agonists or ergot-type medications. For a complete list of contraindications, please consult the Product Monograph.

The recommended single adult dose is 5 mg. The maximum recommended single dose is 10 mg.

The most common adverse events during treatment with MAXALT[®] (rizatriptan benzoate) tablets 10 mg were dizziness (8.9%), somnolence (8.4%), asthenia/fatigue (6.9%), nausea (5.7%) and

pain/pressure sensation (chest, 3.1%; neck/throat/jaw, 2.5%; upper limb, 1.8%).

The most common adverse events during treatment with PrMAXALT RPD[®] (rizatriptan benzoate) wafers 10 mg were dizziness (8.6%), nausea (7.0%), dry mouth (6.0%), somnolence (5.3%), asthenia/fatigue (3.6%), and pain/pressure sensation (chest, 1.7%; neck/throat/jaw, 2.0%; upper limb, 2.0%).

MAXALT RPD[®] wafers contain phenylalanine (a component of aspartame).

*The wafer will dissolve rapidly and be swallowed with saliva. No liquid is needed to take the wafer.²

RPD = Rapidly dissolving

References:

1. Brogan Inc. Geographic Prescription Monitor (GPM[®]) September 2008 to August 2009.
2. Data on file, Merck Frosst Canada Ltd.: Product Monograph, MAXALT[®], 2009.

BEFORE PRESCRIBING **MAXALT**[®], PLEASE CONSULT THE ENCLOSED PRESCRIBING INFORMATION.

PRODUCT MONOGRAPH AVAILABLE FOR DOWNLOAD AT
www.merckfrosst.com

[®]Registered Trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Used under license.

Please visit our website at: www.merckfrosst.com



Merck Frosst Canada Ltd., Kirkland, Quebec



MXT-08-CDN-34381016-JA


A-5

Pr **Maxalt**[®]
(rizatriptan benzoate)

See prescribing summary on page A-14 to A-17

Choose NE migraine therapy that has demonstrated rapid, reliable relief.^{1-4†‡§}

- Demonstrated headache response as quickly as 30 minutes postdose vs. placebo (REL PAX 40 mg: 9%; placebo: 4%, $p < 0.05$)^{1,2†}
- Provided greater relief of associated symptoms vs. sumatriptan 100 mg at 2 hours (absence of nausea: 74% vs. 67%, $p < 0.01$; absence of photophobia: 71% vs. 63%, $p < 0.01$; absence of phonophobia: 74% vs. 67%, $p < 0.01$)^{3‡}
- Demonstrated superior functional response at 2 hours vs. sumatriptan 100 mg (68% vs. 61%, $p < 0.01$; 63% vs. 46%, $p < 0.005$)^{3,4‡§}



REL PAX tablets are indicated for the acute treatment of migraine with or without aura in adults. REL PAX tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of REL PAX tablets have not been established for cluster headache, which is present in an older, predominantly male population. Among 5984 patients who treated a single migraine headache with REL PAX 20 mg, 40 mg or 80 mg tablets in short-term, placebo-controlled trials, the most common and dose-related adverse events reported with treatment with REL PAX were asthenia (7.2%), nausea (7.8%), dizziness (5.7%) and somnolence (5.2%). REL PAX 80 mg is not an available dose. The maximum daily dose is 40 mg.

REL PAX is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) or uncontrolled or severe hypertension should not receive REL PAX. Serious cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm and death, have occurred within a few hours following the use of other 5-HT₁ agonists. These events are extremely rare and have been commonly reported in patients with CAD risk factors or a family history of CAD. REL PAX is contraindicated within 72 hours of treatment with potent CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). REL PAX is contraindicated within 72 hours with drugs that have demonstrated potent CYP3A4 inhibition and have this potent effect described in the CONTRAINDICATIONS, or WARNINGS AND PRECAUTIONS sections of their labeling. REL PAX is contraindicated within 24 hours of treatment with another 5-HT₁ agonist, an ergotamine-containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide. REL PAX is contraindicated in patients with hemiplegic, ophthalmoplegic or basilar migraine, patients with severe hepatic impairment, and those with known hypersensitivity to eletriptan or any of its inactive ingredients.

† In a multicentre, double-blind, placebo-controlled, parallel-group clinical trial, 1334 outpatients with a diagnosis of migraine were randomized to receive REL PAX 20 mg, 40 mg, or 80 mg, or placebo for the treatment of up to 3 migraine attacks. The efficacy, consistency, tolerability and safety of REL PAX were evaluated.

‡ In a randomized, double-blind, double-dummy, parallel-group study conducted in 2113 patients with a diagnosis of migraine. Subjects were randomized to receive REL PAX 40 mg, sumatriptan 100 mg or placebo for the treatment of a single migraine attack.

§ In a randomized, double-blind, double-dummy, placebo-controlled study conducted in 1008 patients with a history of migraine. Subjects were randomized to receive REL PAX 40 mg or 80 mg, sumatriptan 50 mg or 100 mg, or placebo to treat up to 3 migraine attacks.

For complete prescribing information, please refer to the Product Monograph. The Product Monograph is available upon request.



TM Pfizer Inc., used under license
REL PAX[®] Pfizer Products Inc., owner/Pfizer Canada Inc., licensee
© 2009 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5



Working together for a healthier world™



A complete financial diagnosis includes helpful advice and practical solutions.


At Scotiabank, we have experts that can help you grow your business. Our *Scotia Professional*[®] Plan is a customized financial package that includes everything you need to set up and run a successful practice. You'll get competitive financing rates, flexible payback plans, and a dedicated advisor – all in one convenient package to meet your day to day banking, financing, and investment needs. It makes managing your money easy, so you can focus on serving your patients and growing your practice.

Learn more at any Scotiabank branch or visit www.scotiabank.com/professional

Scotia Professional Plan

You're richer than you think.[®]





The Canadian Brain Tumour Consortium & Merck

are pleased to announce the fourth edition of the "Young Investigator Awards" for which graduate students, postdoctoral fellows, residents in training and allied health professionals are eligible.

**Canadian Brain Tumour Consortium
Young Investigator Award in Basic Science**

**Canadian Brain Tumour Consortium
Young Investigator Award in Clinical Investigation**

The Awards will be presented at the:
14th Biennial Canadian Neuro-Oncology Meeting
May 14-16, 2010 – Niagara-on-the-Lake, Ontario

For more information, contact:

Joseph F. Megyesi

Chair, Organizing Committee

Phone: (519) 663-3565 Fax: (519) 663-3419

joseph.megyesi@lhsc.on.ca

sont heureux de lancer la quatrième édition du "Prix d'excellence jeune investigateur". Sont éligibles les étudiants diplômés, les boursiers postdoctorat, les résidents et les auxiliaires médicaux.

**Canadian Brain Tumour Consortium
Prix d'excellence jeune investigateur en Science de base**

**Canadian Brain Tumour Consortium
Prix d'excellence jeune investigateur en Investigation clinique**

Les Prix d'excellence seront présentés à la
14^e Conférence biennale canadienne de neuro-oncologie
du 14 au 16 mai 2010 – Niagara-on-the-Lake, Ontario

Pour plus d'information, veuillez contactez :

Joseph F. Megyesi

Président, comité organisateur

Tél.: 519-663-3565 Téléc.: 519-663-3419

joseph.megyesi@lhsc.on.ca

